Mineralys Therapeutics (MLYS) Short Interest Ratio & Short Volume $9.24 -0.26 (-2.74%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Mineralys Therapeutics Short Interest DataMineralys Therapeutics (MLYS) has a short interest of 1.83 million shares, representing 7.77% of the float (the number of shares available for trading by the public). This marks a 15.09% increase in short interest from the previous month. The short interest ratio (days to cover) is 9.2, indicating that it would take 9.2 days of the average trading volume of 186,831 shares to cover all short positions.Current Short Interest1,830,000 sharesPrevious Short Interest1,590,000 sharesChange Vs. Previous Month+15.09%Dollar Volume Sold Short$22.53 millionShort Interest Ratio9.2 Days to CoverLast Record DateDecember 31, 2024Outstanding Shares49,770,000 sharesFloat Size23,550,000 sharesShort Percent of Float7.77%Today's Trading Volume234,826 sharesAverage Trading Volume186,831 sharesToday's Volume Vs. Average126% Short Selling Mineralys Therapeutics? Sign up to receive the latest short interest report for Mineralys Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMLYS Short Interest Over TimeMLYS Days to Cover Over TimeMLYS Percentage of Float Shorted Over Time Mineralys Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/20241,830,000 shares $22.53 million +15.1%7.8%9.2 $12.31 12/15/20241,590,000 shares $18.92 million +12.8%6.8%8.8 $11.90 11/30/20241,410,000 shares $18.01 million +8.5%6.0%8.1 $12.77 11/15/20241,300,000 shares $14.92 million -6.5%5.5%7.6 $11.48 10/31/20241,390,000 shares $18.60 million -13.7%6.2%8 $13.38 10/15/20241,610,000 shares $22.06 million +1.3%7.2%9.6 $13.70 9/30/20241,590,000 shares $19.25 million +8.2%7.1%8.6 $12.11 9/15/20241,470,000 shares $17.29 million -5.8%6.5%6.8 $11.76 8/31/20241,560,000 shares $19.36 million +7.6%7.0%6.8 $12.41 8/15/20241,450,000 shares $14.15 million -4.0%6.5%6.4 $9.76 Get the Latest News and Ratings for MLYS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Mineralys Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20241,510,000 shares $18.71 million -3.2%7.0%7.4 $12.39 7/15/20241,560,000 shares $22.74 million +36.8%7.4%7.4 $14.58 6/30/20241,140,000 shares $13.34 million +26.0%5.4%6.3 $11.70 6/15/2024904,700 shares $11.38 million -1.7%4.3%6.4 $12.58 5/31/2024920,300 shares $11.75 million -3.1%4.5%6.9 $12.77 5/15/2024949,700 shares $12.41 million -6.0%4.7%7 $13.07 4/30/20241,010,000 shares $12.37 million +15.7%4.5%5.7 $12.25 4/15/2024872,900 shares $10.77 million +2.6%3.8%5.1 $12.34 3/31/2024850,500 shares $10.98 million +1.0%4.8%5 $12.91 3/15/2024842,100 shares $10.69 million -13.5%5.8%4.9 $12.69 2/29/2024974,000 shares $14.98 million +0.9%6.7%5.5 $15.38 2/15/2024965,500 shares $14.46 million +19.1%6.6%5.2 $14.98 1/31/2024810,400 shares $8.84 million -3.2%4.3%4.3 $10.91 1/15/2024836,900 shares $7.78 million -15.5%4.4%4.8 $9.30 12/31/2023990,600 shares $8.52 million +58.5%5.2%5.8 $8.60 12/15/2023625,100 shares $5.04 million -47.9%3.3%3.6 $8.06 11/30/20231,200,000 shares $7.99 million -6.3%6.4%6.7 $6.66 11/15/20231,280,000 shares $8.68 million -9.2%6.8%6.8 $6.78 10/31/20231,410,000 shares $10.90 million -22.1%7.9%6.6 $7.73 10/15/20231,810,000 shares $16.40 million -1.1%10.2%9.7 $9.06 9/30/20231,830,000 shares $17.40 million +3.4%10.3%9.9 $9.51 9/15/20231,770,000 shares $20.37 million +18.8%9.9%8.8 $11.51 8/31/20231,490,000 shares $19.13 million +2.8%8.0%7 $12.84 8/15/20231,450,000 shares $18.08 million +25.0%7.8%7.4 $12.47 7/31/20231,160,000 shares $16.39 million +0.9%6.2%7 $14.13 7/15/20231,150,000 shares $17.85 million +12.8%7.4%7.6 $15.52 6/30/20231,020,000 shares $17.39 million +47.0%6.6%6.8 $17.05 6/15/2023693,900 shares $10.81 million +12.5%4.5%4.9 $15.58 5/31/2023616,800 shares $8.97 million -16.4%4.0%3.7 $14.54 5/15/2023738,000 shares $11.95 million No Change4.8%4.3 $16.19This coin could surge during Trump’s first week in office. (Ad)Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one virtually unknown coin could thrive in the first year of Trump's crypto bull market …starting during his first week in office.Click here to find out more about this coin. MLYS Short Interest - Frequently Asked Questions What is Mineralys Therapeutics' current short interest? Short interest is the volume of Mineralys Therapeutics shares that have been sold short but have not yet been closed out or covered. As of December 31st, investors have sold 1,830,000 shares of MLYS short. 7.77% of Mineralys Therapeutics' shares are currently sold short. Learn More on Mineralys Therapeutics' current short interest. What is a good short interest ratio for Mineralys Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MLYS shares currently have a short interest ratio of 9.0. Learn More on Mineralys Therapeutics's short interest ratio. What is a good short interest percentage for Mineralys Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.77% of Mineralys Therapeutics' floating shares are currently sold short. Is Mineralys Therapeutics' short interest increasing or decreasing? Mineralys Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,830,000 shares, an increase of 15.1% from the previous total of 1,590,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Mineralys Therapeutics' float size? Mineralys Therapeutics currently has issued a total of 49,770,000 shares. Some of Mineralys Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Mineralys Therapeutics currently has a public float of 23,550,000 shares. How does Mineralys Therapeutics' short interest compare to its competitors? 7.77% of Mineralys Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Mineralys Therapeutics: Apogee Therapeutics, Inc. (22.29%), Amphastar Pharmaceuticals, Inc. (13.47%), Tarsus Pharmaceuticals, Inc. (19.17%), Iovance Biotherapeutics, Inc. (24.82%), Disc Medicine, Inc. (11.32%), ImmunityBio, Inc. (7.18%), Wave Life Sciences Ltd. (5.38%), Belite Bio, Inc (0.26%), Galapagos NV (2.51%), Arcutis Biotherapeutics, Inc. (17.92%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short Mineralys Therapeutics stock? Short selling MLYS is an investing strategy that aims to generate trading profit from Mineralys Therapeutics as its price is falling. MLYS shares are trading down $0.26 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Mineralys Therapeutics? A short squeeze for Mineralys Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MLYS, which in turn drives the price of the stock up even further. How often is Mineralys Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MLYS, twice per month. The most recent reporting period available is December, 31 2024. More Short Interest Resources from MarketBeat Related Companies APGE Short Interest AMPH Short Interest TARS Short Interest IOVA Short Interest IRON Short Interest IBRX Short Interest WVE Short Interest BLTE Short Interest GLPG Short Interest ARQT Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MLYS) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.